Ste20-related kinase SLK phosphorylates serl88 of RhoA to induce vasodilation in response to angiotensin II type 2 receptor activation

Circulation Research

Volumn 102, Issue 10, 2008, Pages 1265-1274

  Guilluy, Christophe ^a   Rolli Derkinderen, Malvyne ^a   Loufrani, Laurent ^c   Bourgá, Anne ^a   Henrion, Daniel ^c   Sabourin, Luc ^d   Loirand, Gervaise ^a,b   Pacaud, Pierre ^a,e  

^a L INSTITUT DU THORAX   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CNRS   (France)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e INSERM   (France)

Author keywords

Angiotensin II; Phosphorylation; Rho; Signal transduction; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CASEIN KINASE II; CYCLIC AMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STE 20 RELATED KINASE; UNCLASSIFIED DRUG; ANGIOTENSIN II; CYCLIC AMP DEPENDENT PROTEIN KINASE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS MEGESTROL ACETATE; MEGESTROL ACETATE; NITRIC OXIDE SYNTHASE; PTPN6 PROTEIN, RAT; SLK PROTEIN, RAT; VASOCONSTRICTOR AGENT;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; HYPERTENSION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; THORACIC AORTA; UPREGULATION; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; AORTA, THORACIC; CASEIN KINASE II; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ETHINYL ESTRADIOL; HYPERTENSION; MALE; MEGESTROL ACETATE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 2; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; UP-REGULATION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 45149107475     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.107.164764     Document Type: Article

References (24)

1. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-334.
2. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci. 2006;27: 97-104.
3. Loirand G, Guilluy C, Pacaud P. Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends Cardiovasc Med. 2006; 16:199-204.
4. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 1996;15:510-519.
5. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem. 2000;275: 21722-21729.
6. Rolli-Derkinderen M, Sauzeau V, Boyer L, Lemichez E, Baron C, Henrion D, Loirand G, Pacaud P. Phosphorylation of serine 188 protects RhoA from ubiquitin/prote as ome-mediated degradation in vascular smooth muscle cells. Circ Res. 2005;96:1152-1160.
7. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens. 2005;23:1037-1045.
8. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33: 613-621.
9. Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res. 2004;62:460-467.
10. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005;18:134S-141S.
11. Wagner S, Flood TA, O'Reilly P, Hume K, Sabourin LA. Association of the Ste20-like kinase (SLK) with the microtubule. Role in Racl-mediated regulation of actin dynamics during cell adhesion and spreading. J Biol Chem. 2002;277:37685-37692.
12. Chaar Z, O'Reilly P, Gelman I, Sabourin LA. v-Src-dependent down-regulation of the Ste20-like kinase SLK by casein kinase II. J Biol Chem. 2006;281:28193-28199.
13. Donella-Deana A, Cesaro L, Sarno S, Ruzzene M, Brunati AM, Marin O, Vilk G, Doherty-Kirby A, Lajoie G, Litchfield DW, Pinna LA. Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochem J. 2003;372: 841-849.
14. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab. 2000;11:1-6.
15. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140: 809-824.
16. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341-346.
17. Dimitropoulou C, White RE, Fuchs L, Zhang H, Catravas JD, Carrier GO. Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2 +)-activated K(+) (BK(Ca)) channels. Hypertension. 2001;37:301-307.
18. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor o ver express ion activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
19. Andresen BT, Shome K, Jackson EK, Romero GG. AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity. Am J Physiol Renal Physiol. 2005;288:F763-F770.
20. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spon- taneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens. 2006;24:2417-2422.
21. Tominaga T, Ishizaki T, Narumiya S, Barber DL. p160ROCK mediates RhoA activation of Na-H exchange. EMBO J. 1998;17:4712-4722.
22. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998;63:PL289-PL295.
23. Cui T, Nakagami H, Iwai M, Takeda Y, Shiuchi T, Daviet L, Nahmias C, Horiuchi M. Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc Res. 2001;49:863-871.
24. Sabourin LA, Rudnicki MA. Induction of apoptosis by SLK, a Ste20-related kinase. Oncogene. 1999;18:7566-7575.